Singapore, 30 October 2023 – Recently, the first implantation of the Castor™ Branched Aortic Stent-Graft and Delivery System (Castor™ Branched Stent-Graft) and Hercules™ Thoracic Stent Graft with Low Profile Delivery System covered stent (Hercules™-LP Stent Graft) developed by MicroPort® Endovastec™, was completed at Tan Tock Seng Hospital by Professor Glenn Tan, Professor Pua Uei, Professor Lawrence Quek, and their team. This marks the first clinical use of Endovastec™’s products in Singapore.
The patient, diagnosed with a thoracic aortic aneurysm during a preoperative assessment, had a twisted and narrowed distal neck, a lengthy affected area, a large aneurysm with a maximum diameter exceeding 70 millimeters, and exhibited noticeable symptoms. This necessitated a Thoracic Endovascular Aortic Repair (TEVAR). After a comprehensive evaluation of the patient's imaging data and related measurements, the medical team decided to perform the surgery using a combination of Castor™ Branched Stent-Graft and Hercules™-LP Stent Graft, thereby establishing a more reliable, healthy anchoring zone when isolating the aneurysm.
The operation proceeded smoothly and postoperative angiography revealed precise positioning of the Castor™ Branched Stent-Graft, effectively isolating the aneurysm. The near-end triple small wave segment of the stent displayed excellent sealing without any endoleak or stent migration, and the blood flow in the supra-arch branch vessels remained unobstructed, resulting in a successful surgery.
Thus far, Castor™ Branched Stent-Graft has been introduced into clinical application in 16 countries worldwide, successfully treating over 18,000 patients, and Hercules®-LP Stent Graft has been introduced into clinical application in 18 countries globally, effectively treating more than 58,000 patients with aortic diseases. MicroPort® Endovastec™ will continue its unwavering commitment to advancing comprehensive medical solutions for aortic and peripheral vascular diseases, bringing more high-quality, innovative products to global markets.
About Castor™ Branched Stent-Graft and Hercules™-LP Stent Graft
Castor™ Branched Stent-Graft is designed for endovascular treatment of thoracic aortic dissection involving arch lesions and is the first approved branched aortic stent-graft for the market worldwide. Meanwhile, Hercules™-LP Stent Graft adopts a Low-Profile design, which can adapt to narrower and more tortuous access arteries. It is mainly suitable for endovascular treatment of thoracic aortic aneurysm or Stanford Type B thoracic aortic dissection.
Founded in 2012, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™; SSE: 688016), an associated company of MicroPort Scientific Corporation (MicroPort®; HKEX: 00853), is a global medical device company focusing on R&D, manufacturing, and commercialization of aortic and peripheral vascular interventional devices. Its product portfolio includes thoracic and abdominal aortic stent grafts, stent grafts in surgical operation, peripheral vascular stents, drug-coated PTA balloon catheters etc. At Endovastec™, we are breaking barriers and accelerating access to provide trustworthy and universal access to state-of-the-art total solutions to vascular circulatory diseases, and to build a globally leading group of people centric enterprises of emerging medical technologies through technological innovation.
More information is available at www.endovastec.com.